مالطا - الإنجليزية - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - thiopental sodium - powder for solution for injection - thiopental sodium 500 mg - anesthetics

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 0.03 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; polacrilin potassium - drospirenone/ethinyloestradiol-alphapharm 3/30 is indicated for use as an oral contraceptive.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - probenecid, quantity: 500 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate; stearic acid; magnesium stearate; maize starch; microcrystalline cellulose; povidone; macrogol 8000; hypromellose; macrogol 400; titanium dioxide; sunset yellow fcf; polysorbate 80; quinoline yellow - indications as at 25 may 2000 : gout - probenecid is a uricosuric agent for the treatment of hyperuricaemia in all stages of gout and gouty arthritis except an acute attack. asymptomatic hyperuricaemia seems to occur in a significant percentage of relatives of gouty patients. probenecid may be given prophylactically to these people to forestall gouty attacks and urate deposition in tissues. by virtue of its effective uricosuric activity, probenecid may be used to control the hyperuricaemia induced or aggravated by many diuretics employed for the treatment of oedema and hypertension (e.g. thiazides and smiliar diuretics). b-lactam antibiotic therapy - probenecid is indicated for the elevation and prolongation of plasma levels by whatever route the antibiotic is given. a two-to-fourfold increase in plasma levels has been demonstrated for benzylpenicillin, phenoxymethylpenicillin, the synthetic penicillins, ampicillin, methicillin, oxacillin, cloxacillin, nafcillin, carbenicillin, and for the cephamycin, mefoxin (cefoxitin sodium, msd), and the cephalosporins, cephalothin, cephalexin and cephaloglycin. because of its mechanisim of action, probenecid is not recommended in conjunction with a b-lactam antibiotic in the presence of known renal impairment. concurrent treatment with cidofovir for cmv retinitis in hiv patients. probenecid is recommended to be administered concomitantly with cidofovir, as the combination reduces the potential for nephrotoxicity associated with cidofovir.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine sulfate pentahydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose; croscarmellose sodium - anamorph is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - propantheline bromide, quantity: 15 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; purified talc; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications were approved as specified in the letter of 7 april 1993 from dr l. hunt are as follows: as an adjunctive therapy in the treatment of peptic ulcer (gastric and duodenal), neurogenic bladder, urinary incontinence in patients with detrusor hyperactivity and hyperhidrosis.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - oxybutynin hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; brilliant blue fcf aluminium lake; lactose; calcium stearate - treatment of detrusor over-activity where conservative measures have failed.